Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Frequently Asked Questions
What is market cap of Bio-Techne Corp?
The market cap of Bio-Techne Corp is $11.55B
What is the 52 week high for Bio-Techne Corp?
The 52 week high for Bio-Techne Corp is $113.81.
What is the 52 week low for Bio-Techne Corp?
The 52 week low for Bio-Techne Corp is $68.00.
What is Bio-Techne Corp stock price today?
Bio-Techne Corp' stock price today is $73.41.
What is the pe ratio of Bio-Techne Corp?
The PE ratio of Bio-Techne Corp is 45.61.
What is the price to book ratio of Bio-Techne Corp?
The price to book ratio of Bio-Techne Corp is 6.3118.
What is Bio-Techne Corp's EBITDA?
Bio-Techne Corp's EBITDA is 355.451.
What is the 50-day moving average of Bio-Techne Corp?
The 50-day moving average of Bio-Techne Corp is 76.342.